Avanos Medical, Inc. (NYSE:AVNS) Q4 2023 Earnings Call Transcript

Joe Woody: So, look our primary focus is getting the precise execution that we need in the business. We have successfully executed the product ex-US. Investing in orange is the RH business and acquiring technology with euros. We obviously approved an additional share repurchase program and deliver most of our financial objectives. And I think, we’ve established the necessary foundation to deliver on the midterm financial commitments and confident that our transformation priorities coupled with our market-leading portfolio are attractive markets does position us for sales growth margin expansion and meaningful free cash flow generation. So we appreciate everybody’s continued interest in hours, and I’m sure we’ll speak further throughout the week. Thank you.

Operator: Thank you. This concludes today’s conference call. We thank you all for attending today’s presentation. You may now disconnect your lines. Have a good day.